Encompass Health Corporation · EHC · FY2026 Q1 · Calendar Q2 2026
EHC raises 2026 outlook as capacity expansion targets strong rehab demand
The supplied analysis supports a constructive operating thesis for EHC: demand for inpatient rehabilitation remains strong, and capacity additions plus improved labor performance support continued growth. The thesis depends on converting high occupancy into profitable new capacity while managing reimbursement changes, Medicare Advantage dynamics, and rising capital needs.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about EHC FY2026 Q1
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management moved from maintained to raised guidance. The current analysis adds a 17.8% RN-turnover result, a new 49-bed hospital, plans for seven additional hospitals and further bed additions, and early evidence from an admit-and-appeal pilot.
Guidance delta
Management raised 2026 revenue, adjusted EBITDA, and EPS guidance after Q1.
Key takeaways
- Q1 revenue and EBITDA exceeded expectations, supporting a 2026 guidance increase.
- RN turnover reached 17.8%, the lowest level since 2012, alongside career-ladder and centralized hiring efforts.
- Expansion includes a new 49-bed hospital, seven planned hospitals totaling 340 beds, and additional existing-site capacity.
- Occupancy above 90% in high-growth markets is accelerating new-bed planning.
- Medicare Advantage penetration has plateaued or receded, while an admit-and-appeal pilot is showing early promise.
Management priorities
- Add hospitals and beds in high-growth markets.
- Scale small-format hospitals and the hub-and-spoke model.
- Sustain lower turnover through career-ladder and talent-acquisition programs.
- Evaluate and expand the Medicare Advantage admit-and-appeal pilot.
- Manage TEAM, RCD, and other reimbursement changes.
Follow EHC with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 1, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Buy | Maintain | Oct 30, 2026 |
| Truist Securities | Buy | Buy | Maintain | Oct 30, 2026 |
| TD Cowen | Buy | Buy | Maintain | Oct 30, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Oct 30, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 29, 2026 |
| B of A Securities | Buy | Buy | Maintain | Sep 10, 2025 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jun 5, 2025 |
| RBC Capital | Outperform | Outperform | Maintain | Apr 28, 2025 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Apr 26, 2024 |
| Mizuho | Buy | Buy | Maintain | Apr 25, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 4, 2023 |
| Deutsche Bank | Buy | Buy | Maintain | May 1, 2023 |
| BMO Capital | Outperform | Outperform | Maintain | Aug 4, 2022 |
| Jefferies | Buy | Buy | Maintain | Jul 27, 2020 |
| Baird | Outperform | Outperform | Maintain | Mar 5, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Feb 10, 2020 |
| Wells Fargo | Underweight | Equal Weight | Downgrade | Dec 11, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Sep 6, 2019 |
| William Blair | Outperform | Outperform | Maintain | Nov 21, 2017 |
| Craig-Hallum | Buy | Buy | Maintain | Feb 14, 2017 |
| PiperJaffray | Neutral | Neutral | Maintain | Jan 4, 2017 |
| Stifel Nicolaus | Hold | Buy | Downgrade | Oct 29, 2015 |
| JMP Securities | Outperform | Market Perform | Upgrade | Jul 2, 2015 |
| Wedbush | Neutral | Neutral | Maintain | Jun 10, 2015 |
| Susquehanna | Outperform | Positive | Maintain | Jul 26, 2013 |
| Lazard | Buy | Buy | Maintain | Jul 24, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $135.9. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Raymond James | Andrew Cooper | $155 | $135.9 | +14.1% | Oct 30, 2026 |
| UBS | Analyst unavailable | $165 | $131.49 | +21.4% | Oct 30, 2026 |
| KeyBanc | Matthew Gillmor | $150 | $131.49 | +10.4% | Oct 30, 2026 |
| Truist Financial | David MacDonald | $156 | $131.49 | +14.8% | Oct 30, 2026 |
| Barclays | Analyst unavailable | $151 | $122.09 | +11.1% | Oct 29, 2026 |
| Raymond James | Andrew Cooper | $150 | $123.47 | +10.4% | Sep 28, 2026 |
| Truist Financial | David MacDonald | $150 | $125.42 | +10.4% | Aug 7, 2026 |
| UBS | Analyst unavailable | $155 | $125.45 | +14.1% | Aug 7, 2026 |
| Barclays | Analyst unavailable | $144 | $110.9 | +6.0% | Aug 6, 2026 |
| Leerink Partners | Whit Mayo | $152 | $104.45 | +11.8% | May 22, 2026 |
| Barclays | Analyst unavailable | $140 | $106.64 | +3.0% | May 5, 2026 |
| Barclays | Analyst unavailable | $153 | $99.56 | +12.6% | Feb 6, 2026 |
| Barclays | Andrew Mok | $150 | $125.63 | +10.4% | Oct 30, 2025 |
| UBS | Analyst unavailable | $150 | $124.52 | +10.4% | Oct 2, 2025 |
| Truist Financial | David MacDonald | $140 | $119.3 | +3.0% | Aug 14, 2025 |
| RBC Capital | Analyst unavailable | $125 | $115.32 | -8.0% | Apr 28, 2025 |
| RBC Capital | Ben Hendrix | $105 | $96.75 | -22.7% | Sep 26, 2024 |
| UBS | AJ Rice | $110 | $95.26 | -19.1% | Sep 25, 2024 |
| RBC Capital | Frank Morgan | $95 | $85.86 | -30.1% | May 22, 2024 |
| Mizuho Securities | Ann Hynes | $95 | $82.8 | -30.1% | Apr 25, 2024 |
| Barclays | Andrew Mok | $101 | $81.79 | -25.7% | Mar 28, 2024 |
| RBC Capital | Analyst unavailable | $85 | $68.24 | -37.5% | May 3, 2022 |
| Raymond James | Analyst unavailable | $85 | $68.83 | -37.5% | May 2, 2022 |
| Credit Suisse | Analyst unavailable | $83 | $68.46 | -38.9% | Apr 29, 2022 |
| Stephens | Scott Fidel | $100 | $84.62 | -26.4% | Apr 29, 2021 |
Track every rating change on EHC the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationEncompass Health Corporation delivers a range of post-acute healthcare services across the United States, offered both in dedicated facilities and directly within patients' homes. The company's operations are divided into two primary divisions: Inpatient Rehabilitation, and Home Health and Hospice. Its Inpatient Rehabilitation division specializes in providing focused recovery treatment, available on an inpatient or outpatient basis. This care is designed for individuals recuperating from significant health challenges such as strokes, neurological disorders, cardiac and pulmonary issues, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment primarily serves the Southeast and Texas regions.…
Historical context
All EHC earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the EHC recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-01T12:10:42.058420+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-01T12:10:42.055241+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-01. For educational purposes only; not investment advice.